Metraipolis › archive › dc_20135af44360

Outcomes of Nivolumab-Plus-Ipilimumab in Metastatic Renal Cell Carcinoma: Second Interim Analysis of the J-ENCORE Study — Europe PMC PMID:41292059

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41292059
DOI
10.1111/iju.70281
License (as archived)
solo-consultazione
Archived
2026-11-08T06:52:19.975Z
SHA-256 of the archived text
ee6c22487eafaea747eb6a1d6fc34be281fcd110934efa5c3970f46529682047
Stable URL of this page
https://metraipolis.com/documento/dc_20135af44360

How to cite

Outcomes of Nivolumab-Plus-Ipilimumab in Metastatic Renal Cell Carcinoma: Second Interim Analysis of the J-ENCORE Study — Europe PMC PMID:41292059 — Europe PMC (en), https://europepmc.org/article/MED/41292059 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_20135af44360 (Metraipolis archive dc_20135af44360, sha256 ee6c22487eafaea747eb6a1d6fc34be281fcd110934efa5c3970f46529682047)
BibTeX
@misc{dc20135af44360,
  title = {Outcomes of Nivolumab-Plus-Ipilimumab in Metastatic Renal Cell Carcinoma: Second Interim Analysis of the J-ENCORE Study — Europe PMC PMID:41292059},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41292059},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_20135af44360; sha256 ee6c22487eafaea747eb6a1d6fc34be281fcd110934efa5c3970f46529682047},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41292059. Agents can read the archived copy with the MCP tool read_document.